Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.
about
New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisonsAssessing bleeding risk in patients taking anticoagulantsDirect-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine PhysiciansNovel oral anticoagulants and the 73rd anniversary of historical warfarinThe evolution of anticoagulant therapyRisk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational StudiesClinical research priorities in adult congenital heart diseaseThe Reversal of Direct Oral Anticoagulants in Animal Models.Apixaban, concomitant medicines and spontaneous reports of haemorrhagic events.Global deregulation of ginseng products may be a safety hazard to warfarin takers: solid evidence of ginseng-warfarin interactionClinical trials registries are under-utilized in the conduct of systematic reviews: a cross-sectional analysis.Approach to the new oral anticoagulants in family practice: part 1: comparing the options.Reciprocal allosteric modulation of carbon monoxide and warfarin binding to ferrous human serum heme-albuminComparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort studyNon-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis.Adherence to oral anticoagulants in patients with atrial fibrillation-a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol.The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulantsEuropean Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care.Noncanonical matrix metalloprotease-1-protease-activated receptor-1 signaling triggers vascular smooth muscle cell dedifferentiation and arterial stenosis.Patient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding.The new oral anticoagulants in atrial fibrillation: an updatePrevention of venous thromboembolism in patients undergoing surgical treatment of varicose veins.Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants.Novel oral anticoagulants for atrial fibrillation.Oral anticoagulants to reduce the risk of stroke in atrial fibrillation: how should a clinician choose?New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants.Should we be looking for and treating isolated calf vein thrombosis?Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.A retrospective study on the risk factors for bleeding events in warfarin therapy, focusing on renal function.Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials.A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras.Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists.PURLs: Direct oral anticoagulants or warfarin for A fib?At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS)Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults - a systematic review of reviews and the development of recommendations to reduce inappropriate presAn international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran.Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal.
P2860
Q21132464-D6E4D99E-56D3-4E83-AD36-796BA18A01D0Q24619070-C5D69289-F26A-4A0C-A9BF-19F95DD088D0Q26746917-FDEBEEB9-B649-41F0-89D7-56477B2A2E27Q26771544-2D76DBF5-253B-4E6E-A2D9-B5829B15F0C6Q26771859-03A89336-D283-4324-A954-6CB1DE0F2C29Q28078747-A46E2230-A423-482C-B532-DE536260BFC5Q30418760-8BE1E957-833F-40DF-8080-5CBE0FCA3EEDQ30491580-8D281DA1-BB18-4F89-9B93-07D3E8973291Q33727817-DDE36336-4323-4812-BE57-C01A6C177A1AQ33918604-B51DB974-D211-4BFC-89A3-11216BAB1BDFQ34441631-B5E68DAF-BAB8-46D1-BC54-1EA0E7410C51Q34497581-E3C93FED-943A-4539-BB2E-92D71BF9243DQ34650567-1E257B69-579E-4BA1-9CF5-709CBF0E677DQ35079761-190FDEDE-1B3C-48FF-8D96-682917ADC140Q35153009-02179B6E-AD24-4C7F-B77C-309FDF7E2353Q35650348-BDF2F062-669A-4443-8525-175130283AD7Q35681742-7452C306-9813-4CF4-A9AA-5A03ECAD6144Q36179688-79B34A57-F6CB-4E7E-B732-6356F51B1D10Q36396649-CE63D7A4-B343-43DD-A448-9D17DB0B9851Q36617346-DCDD5552-ACA6-42B2-BF4C-07E6F7877F35Q37095396-F7AA1BB5-EA9B-4828-9311-92D24A11746CQ37114565-F50DC225-82BF-426A-9B99-7558A8D00015Q37299820-D6925C64-21A8-4963-AEC7-6F7BF010C743Q38088603-B0C7232E-586E-4CBA-A217-DA692DD38EFCQ38113097-33D1C5EA-F612-496D-8673-94CDD03B46FBQ38114002-1C445098-FFC8-41FE-8D44-076E08135843Q38124826-52A52DE6-BFB5-4A4C-B2D9-BAE32749EDB4Q38166368-A808C268-FFDC-4C34-82AF-15364F04F0BAQ38535096-E3FF8A34-32D2-4216-A89B-8BDDA4D73C25Q38602280-5A61DF2B-BB8F-4E74-B57B-E7B99694967CQ38631166-8FE3EEC8-EA57-4BA0-A7B4-8ABDDFAF82F1Q38991392-FFF34B4D-4A8A-4F14-B9DB-A6D361B7DADBQ39637963-79EB27A1-CD5F-49D2-A638-F900A7537B1CQ39787308-FBF5B1FE-E8E1-49C9-A3B7-BB124DB64EB8Q40731819-4797734B-8028-4E86-9799-E88ED38E0D5AQ41322647-6A29ECA5-D2C1-4C5D-A841-B08161D81BDAQ42001234-A5155E1B-F84E-4880-8E2D-26608005C51EQ42676634-754638C3-C22C-4F12-B300-31C9802582F4Q44565267-22D79D6B-6BEA-4537-91CB-549902840BA9Q44773326-38C13707-291F-4FCF-A760-EC4208E87787
P2860
Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Comparative effectiveness of w ...... embolism: a systematic review.
@ast
Comparative effectiveness of w ...... embolism: a systematic review.
@en
Comparative effectiveness of w ...... embolism: a systematic review.
@nl
type
label
Comparative effectiveness of w ...... embolism: a systematic review.
@ast
Comparative effectiveness of w ...... embolism: a systematic review.
@en
Comparative effectiveness of w ...... embolism: a systematic review.
@nl
prefLabel
Comparative effectiveness of w ...... embolism: a systematic review.
@ast
Comparative effectiveness of w ...... embolism: a systematic review.
@en
Comparative effectiveness of w ...... embolism: a systematic review.
@nl
P2093
P921
P1476
Comparative effectiveness of w ...... embolism: a systematic review.
@en
P2093
Jennifer R McDuffie
John W Williams
Soheir S Adam
Thomas L Ortel
P304
P356
10.7326/0003-4819-157-10-201211200-00532
P407
P577
2012-12-01T00:00:00Z